Gilead Sciences reported $934M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Agios Pharmaceuticals USD 19.93M 3.58M Sep/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Eli Lilly USD 5.79B 319M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
GlaxoSmithKline GBP 15.63B 1.29B Sep/2026
Glaxosmithkline GBP 15.63B 1.3B Sep/2026
Incyte USD 235.37M 1.16B Sep/2026
J&J USD 9.32B 94M Sep/2026
Merck USD 5.03B 1.2B Sep/2026
Moderna USD 259M 92M Sep/2026
Neurocrine Biosciences USD 754.1M 612.1M Sep/2026
Novartis USD 4.24B 15M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 24.55B 957M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
United Therapeutics USD 520.2M 22.4M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026